CAJ | 학술논문

目的通过检测肝癌患者血清中的GP73含量,探讨其对于肝癌诊断和临床治疗的意义.方法利用上转发光免疫呈析技术对302例肝癌、慢性肝炎、肝硬化患者和正常对照血清样本进行GP73含量检测,同时应用电化学发光方法检测AFP作为比较.并应用ROC曲线分析其诊断效能,并对HCC患者进行治疗前后GP73定期检测分析治疗效果.结果肝癌患者GP73含量为(160.83±37.24) ng/ml,显著高于慢性肝炎、肝硬化患者和正常对照；GP73在诊断肝癌和慢性肝炎和肝硬化的ROC曲线下面积为0.907,高于AFP的ROC曲线下面积0.727；并确定110 ng/ml最为其临界值,其敏感性为84.7％,特异度为75.8％；对AFP＜ 400 ng/ml肝癌患者,GP73的检出率为71.15％；治疗后GP73含量总体呈现下降趋势.结论 GP73对于HCC诊断具有较高的灵敏性,可补充AFP在灵敏性方面的不足,可用于监测肝癌治疗效果.
목적 통과검측간암환자혈청중적GP73함량,탐토기대우간암진단화림상치료적의의.방법 이용상전발광면역정석기술대302례간암、만성간염、간경화환자화정상대조혈청양본진행GP73함량검측,동시응용전화학발광방법검측AFP작위비교.병응용ROC곡선분석기진단효능,병대HCC환자진행치료전후GP73정기검측분석치료효과.결과 간암환자GP73함량위(160.83±37.24) ng/ml,현저고우만성간염、간경화환자화정상대조；GP73재진단간암화만성간염화간경화적ROC곡선하면적위0.907,고우AFP적ROC곡선하면적0.727；병학정110 ng/ml최위기림계치,기민감성위84.7％,특이도위75.8％；대AFP＜ 400 ng/ml간암환자,GP73적검출솔위71.15％；치료후GP73함량총체정현하강추세.결론 GP73대우HCC진단구유교고적령민성,가보충AFP재령민성방면적불족,가용우감측간암치료효과.
Objective By the detection of hepatocellular carcinoma in patients with GP73 content to explore its significance for liver cancer diagnosis and clinical treatment.Methods Up-converting phosphor immunochromatography methods was used for detection of serum GP73 in 302 cases of liver cancer,chronic hepatitis,cirrhosis patients and normal control,application electrochemiluminescence detection of AFP as a comparison.And ROC curve analysis of its diagnostic performance,and patients with HCC before and after treatment GP73 periodic testing of the treatment effect.Results GP73 content of liver cancer patients was (160.83 ± 37.24) ng/ml,significantly higher than the chronic hepatitis,cirrhosis patients and normal controls.The area under ROC curve for GP73 diagonosis of hepatocellular carcinoma and chronic hepatitis and cirrhosis was 0.907 which higher than the area under the ROC curve of AFP was 0.727.Determine 110ng/ml most of its critical value,the sensitivity was 84.7％,specificity was 75.8％ ; liver cancer patients with AFP ＜ 400 ng/ml,detection rate of GP73 was 71.15％ ; the GP73 content after treatment showing an overall downward trend.Conclusion GP73 has a high sensitivity for the diagnosis of HCC can add to the AFP's lack of sensitivity that can be used to monitor liver cancer treatment.